Skip to main content
logo
Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
105.50
-0.25 (-0.24%)
At close: Aug 29, 2025, 4:00 PM
105.75
+0.25 (0.24%)
After-hours: Aug 29, 2025, 7:52 PM EDT

Boston Scientific Revenue by Segment

Period EndingJun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Cardiology
9.50B8.90B8.35B7.80B7.32B6.97B6.71B6.49B
Cardiology Growth
29.86%27.65%24.40%20.24%15.81%13.75%13.08%11.35%
Endoscopy
2.78B2.72B2.69B2.64B2.59B2.55B2.48B2.41B
Endoscopy Growth
7.18%6.67%8.22%9.68%10.86%12.35%11.75%9.06%
Peripheral Interventions
2.60B2.49B2.41B2.30B2.23B2.18B2.11B2.05B
Peripheral Interventions Growth
16.43%14.41%14.27%11.99%12.09%12.55%11.12%8.92%
Urology
2.47B2.32B2.20B2.10B2.05B2.01B1.96B1.91B
Urology Growth
20.65%15.54%12.02%9.56%9.87%9.79%10.77%10.19%
Neuromodulation
1.14B1.12B1.11B1.08B1.04B998.00M976.00M956.00M
Neuromodulation Growth
10.14%12.22%13.22%12.45%9.28%5.83%6.32%4.71%
Specialty Pharma
-----------------191.00M219.00M241.00M

Revenue by Geography

Period EndingJun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
United States
11.67B10.91B10.21B9.53B9.04B8.68B8.43B8.20B
United States Growth
29.15%25.71%21.19%16.25%12.49%10.49%10.40%10.14%
EMEA
3.33B3.27B3.23B3.15B3.05B2.95B2.86B2.76B
EMEA Growth
9.26%11.03%13.06%13.90%13.75%12.70%13.02%9.17%
APAC
2.86B2.74B2.69B2.62B2.54B2.50B2.40B2.32B
APAC Growth
12.38%9.56%11.83%12.75%13.47%16.50%13.52%8.56%
LACA
638.00M631.00M625.00M618.00M605.00M583.00M560.00M534.00M
LACA Growth
5.45%8.23%11.61%15.73%19.33%19.71%19.66%17.88%
Specialty Pharma
-----------------191.00M219.00M241.00M

Operating Expense Breakdown

Period EndingJun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Selling, General, and Administrative
6.49B6.22B5.98B5.75B5.43B5.34B5.19B4.97B
Selling, General, and Administrative Growth
19.44%16.45%15.30%15.62%11.66%14.20%14.82%10.29%
Research and Development
1.84B1.69B1.62B1.52B1.47B1.44B1.42B1.38B
Research and Development Growth
25.07%17.24%14.20%9.91%7.55%7.68%6.95%5.26%
Amortization
874.00M862.00M857.00M840.00M843.00M840.00M829.00M820.00M
Amortization Growth
3.68%2.62%3.38%2.44%3.56%3.96%3.24%3.02%
Asset and Goodwill Impairment
434.00M-445.00M-459.00M--190.00M386.00M--457.00M377.00M-509.00M--
Asset and Goodwill Impairment Growth
12.44%--2.63%-21.75%---62.67%-27.31%--4.58%-36.10%----
Litigation-related Net Charges
-------190.00M--599.00M-472.00M-448.00M-580.00M505.00M--
Litigation-related Net Charges Growth
--------67.24%--18.61%---------
Restructuring Net Charges
105.00M23.00M16.00M31.00M38.00M53.00M70.00M57.00M
Restructuring Net Charges Growth
176.32%-56.60%-77.14%-45.61%-17.39%29.27%180.00%35.71%
Royalty Expense
43.00M38.00M34.00M36.00M42.00M45.00M46.00M47.00M
Royalty Expense Growth
2.38%-15.56%-26.09%-23.40%-10.64%-2.17%-2.13%4.44%
Loss on Disposal of Assets
----------34.00M---18.00M-----
Contingent Consideration Net Expense
-24.00M-17.00M-5.00M10.00M45.00M62.00M57.00M10.00M-
Contingent Consideration Net Expense Growth
----150.00%77.14%62.86%-80.00%-
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.